We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Risk Loci Identified for Polycystic Ovary Syndrome

By LabMedica International staff writers
Posted on 09 Jan 2019
Polycystic ovary syndrome is a disorder characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology. More...
Affected women frequently have metabolic disturbances including insulin resistance and dysregulation of glucose homeostasis.

Polycystic ovary syndrome (PCOS) is diagnosed with two different sets of diagnostic criteria, resulting in a phenotypic spectrum of PCOS cases. The genetic similarities between cases diagnosed based on the two criteria have been largely unknown.

An international team of scientists working with the University of Utah (Salt Lake City, UT) performed a genome-wide association study meta-analysis involving 10,074 individuals with PCOS and 103,164 without, leading to three previously undetected loci and 11 loci linked to the endocrine disorder in the past. Of those, 13 loci were associated with self-reported PCOS and cases diagnosed using National Institutes of Health or Rotterdam criteria.

PCOS diagnoses are based on excess androgen hormone levels and ovulatory dysfunction, the team explained, which represents roughly 7% of reproductive age women around the world. On the other hand, more general criteria from Rotterdam defined PCOS as polycystic ovarian morphology in combination with either hyperandrogenism or ovulatory dysfunction, representing an estimated 15% to 20% of women globally.

The team reported new associations at loci in or around the PLGRKT, ZBTB16, and MAPRE1 genes, which are believed to contribute to metabolic and reproductive pathways. The meta-analysis also led to 11 known risk loci, which were overrepresented for variants in and around genes from neuroendocrine and metabolic pathways. The set of known risk loci included half a dozen sites previously implicated in PCOS in women of Han Chinese ancestry, and a variant near the GATA4/NEIL2 genes that showed strong ties to the PCOS diagnosed using NIH criteria but weaker associations to the self-reported PCOS cases.

The authors concluded that the genetic underpinnings of PCOS implicate neuroendocrine, metabolic, and reproductive pathways in the pathogenesis of disease. Although specific phenotype stratified analyses are needed, genetic findings were consistent across the diagnostic criteria for all but one susceptibility locus, suggesting a common genetic architecture underlying the different phenotypes. The study was published on December 19, 2018, in the journal PLOS Genetics.

Related Links:
University of Utah


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.